Developer docs
API playgroundTry for free, no card

Search company profiles

BitBiome

Full company profile

uuid00021uj

Namestring
BitBiome
Legal namestring
bitBiome, Inc.
Websiteurl
bitbiome.bio
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BitBiome is a Tokyo-headquartered biotechnology company, founded in 2018, that operates a vertically integrated platform for microbial genomics and AI-driven enzyme engineering. The platform has three core components: bit-MAP, a proprietary single-cell microbial genome sequencing technology; bit-GEM, a proprietary microbial genome database containing more than 2.5 billion sequences of which approximately 50% are novel; and bit-QED, an AI/ML-based enzyme design platform that combines structural modeling, large language models, and in silico directed evolution. BitBiome also maintains a US presence in Palo Alto, California, supporting commercial and partnership activity in North America.

The company sells into industrial biotechnology customers across food and ingredients (Ajinomoto, Sanwa Starch), specialty chemicals (Tokyo Ohka Kogyo), personal care (Kao), textiles and bio-recycling (Bell Polyester under NEDO funding), animal health (Kyoritsu Seiyaku), distribution (Tojo Vikas for India), and life sciences tools (Twist Bioscience for enzyme kit distribution), plus an unnamed flavors and fragrances market leader. Revenue is generated through a mix of custom sequencing service contracts, joint development agreements with milestone or licensing components, grant-funded research programs (NEDO and AMED), and an emerging standardized enzyme/reagent kit channel via Twist Bioscience. Total capital raised across equity and non-dilutive funding exceeds $45M as of a 2026 oversubscribed seed extension, with strategic participation from IQT, IT-Farm, Valuence Ventures, and Darwin Ventures. The company was named to the Forbes Asia 100 To Watch list in 2025.

The business model is best characterized as a hybrid services-plus-platform model: short- to medium-term cash flow comes from sequencing services and JDAs, non-dilutive grant income supports longer-horizon platform R&D, and the strategic optionality of bit-QED and bit-GEM is positioned to generate higher-margin licensing or royalty income over time as customer programs mature.

Short descriptiontext

BitBiome is a Tokyo-based microbial genomics company combining proprietary single-cell sequencing, a 2.5B+ sequence database, and AI-driven enzyme engineering to serve industrial biotech customers in food, chemicals, personal care, animal health, and bio-recycling.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbial genome sequencing, enzyme engineering services, synthetic biology platform, biomanufacturing solutions, metagenomics database
Industry2 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Microbial Genomics & Enzyme Engineering Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Enzyme Discovery, Engineering, and Strain Development Services
TypeProfessional Services
Description

Custom B2B fee-for-service revenue from database mining, assaying, directed evolution, and strain engineering using bit-QED. Engagement is typically project-based with flexible scope (single-step to end-to-end workflow including wet lab validation and production).

bitbiome.bio
2Sequencing Services (bit-MAP®)
TypeProfessional Services
Description

Fee-based single-cell microbial sequencing services delivered via a Collect → Ship → Receive Report workflow with full bioinformatics report (taxonomies, novelty, completeness, contamination). Includes human, animal, and environmental samples.

bitbiome.bio
3Enzyme Kit Product Sales (via Twist Bioscience)
TypeOne Time License
Description

bitBiome's enzyme screening kit (48 validated transaminases across 18 substrates with freeze-dried enzymes, yielding 1,800 variants after six rounds of refinement) is commercialized through Twist Bioscience's storefront. Revenue likely flows via distribution agreement.

bitbiome.bio
4Joint Development, Manufacturing & Supply Partnerships
TypeManaged Services
Description

Revenue from joint development and manufacturing collaborations where bitBiome develops bio-based production processes and serves as manufacturing/supply partner upon commercialization (e.g., food-grade flavor & fragrance ingredient collaboration with double-digit metric ton annual demand; PET bio-recycling with Bell Polyester Products).

worldbiomarketinsights.com
5Public/Grant (Non-Dilutive) Funding
TypeSubscription Recurring
Description

bitBiome receives non-dilutive funding from Japanese government programs (NEDO Biomanufacturing Revolution Promotion Program; AMED P-PROMOTE Next-Generation Cancer Medical Acceleration Research Project with Nagoya University; JST PRESTO), which supplements its commercial revenue streams.

bitbiome.bio
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1bit-MAP®
Description

bitBiome's patented single-cell sequencing technology for microbes using microfluidics to capture and sequence individual bacterial genomes within isolated capsules; 100x more efficient than shotgun metagenomics.

bitbiome.bio
+2 more records
Core offering1 text field

BitBiome provides a microbial biomanufacturing platform combining proprietary single-cell microbial genome sequencing (bit-MAP®), a proprietary microbial sequence database (bit-GEM, 2.5B+ sequences), and an AI-driven enzyme and strain engineering platform (bit-QED) that uses bioinformatics, cheminformatics, machine learning, and large language models for in silico enzyme design and directed evolution. The platform is delivered to enterprise customers as fee-for-service sequencing, custom enzyme discovery and engineering, and joint development/manufacturing partnerships spanning pharmaceuticals, food & agriculture, materials & plastics, flavors & fragrances, and life science tools.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 100x more efficient gene analysis than shotgun metagenomics
+8 more records
Product overview1 text field

bitBiome operates a unified microbial biomanufacturing platform built around three tightly integrated core modules: bit-MAP® (the patented single-cell microbial sequencing engine that powers data generation), bit-GEM (the proprietary microbial genome catalog of 2.5+ billion sequences grown from bit-MAP outputs), and bit-QED (the AI-driven enzyme discovery, engineering, and strain development platform that mines and engineers sequences from bit-GEM). These three modules together form the foundation of the offering, which is delivered to customers through complementary products and services: Sequencing Services (single-cell sequencing-as-a-service with bioinformatics reporting) and a commercial Enzyme Kit (a Twist Bioscience-distributed transaminase screening kit for ownable enzyme development). The platform also supports internal R&D pipeline development across Food & Agriculture, Materials & Textiles, Plastics, Drug Discovery, Drug Biomanufacturing, Synbio, and Gene Editing applications, and is positioned as a one-stop-shop from microbial discovery through commercial-scale biomanufacturing.

Product and service5 records
1bit-MAP®
CategoryCore sequencing technology
Description

Patented single-cell microbial sequencing technology that uses microfluidics to capture and sequence individual bacterial genomes inside isolated capsules, eliminating the need for culturing. Reported as 100x more efficient than shotgun metagenomics and capable of recovering microbial dark matter from low-biomass and high-diversity samples. Foundation of BitBiome's platform.

2bit-GEM
CategoryCore database / catalog
Description

Proprietary microbial genome database of 2.5 billion sequences (and growing by ~1 billion per year) built on bit-MAP single-cell sequencing of microbes from natural samples, including unculturable and extremophile sources. Approximately 60% of samples are environmental and ~50% taxonomically novel compared with public databases.

3bit-QED
CategoryCore enzyme discovery and engineering platform
Description

AI-driven enzyme discovery, engineering, and strain development platform that combines sequence and structure-based mining of bit-GEM with machine learning, large language models, 3D structural modeling, and automated wet-lab high-throughput screening. Reduces a 2-3 year process to months or weeks and is positioned as a one-stop-shop for biomanufacturing.

4Sequencing Services
CategoryService offering
Description

Single-cell microbial sequencing-as-a-service: customers collect human/animal/environmental samples and ship them to bitBiome, which delivers a full bioinformatics report including taxonomies. Includes a miniaturized multi-drop metagenomics workflow providing 10x the data while retaining single-cell resolution.

5Enzyme Kit (Transaminase Screening Kit)
CategoryCommercial product / kit
Description

Kick-start enzyme development kit leveraging 48 validated unique transaminases tested against 18 different substrates, delivered as freeze-dried enzymes. Six rounds of bitBiome's bioinformatics and refinement yield 1,800 new variants for testing. Commercialized in partnership with Twist Bioscience.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-09
Description

Strategic collaboration to jointly develop products utilizing bitBiome's bio-manufacturing technologies for animal health and nutrition. Kyoritsu Seiyaku contributes decades of veterinary experience for pets and livestock; commercialize jointly in global market.

2Unnamed major market leader in flavors & fragrances
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Joint development and manufacturing collaboration to create a bio-synthetic production process for a high-value food-grade ingredient used in flavors and fragrances. Initial demand projected at double-digit metric tons per year.

worldbiomarketinsights.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Joint implementation of NEDO-commissioned 'Research and Development of Technologies to Promote Biomanufacturing' project to establish a saccharification enzyme supply platform that enables use of unused biomass resources. bitBiome handles enzyme discovery work.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Strategic joint development and commercialization collaboration for sustainable flavor and fragrance biomanufacturing. Combines bitBiome's proprietary microbial database and bio-manufacturing platform with Tojo Vikas' market knowledge and ingredient commercialization expertise.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-08-06
Description

Selected together for NEDO 'Bio-recycling of Waste Plastic Resources' project — bitBiome develops proprietary enzymes using bit-QED, Bell Polyester Products produces bio-recycled co-polymerized PET resin via Bio BellPET line.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-07
Description

Enzyme development contract under NEDO Biomanufacturing project 'Development and Social Implementation of Functional Sugar Materials from Untapped Domestic Biomass.' bitBiome uses bit-QED to discover and supply saccharification enzymes.

7Nagoya University (Tokai National Higher Education and Research System)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-06-16
Description

Collaboration under AMED P-PROMOTE Next-Generation Cancer Medical Acceleration Research Project to develop combination therapy of Fusobacterium-specific endolysin and immune checkpoint inhibitors for ovarian cancer.

bitbiome.bio
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-30
Description

Joint development agreement to develop bio-processes using bitBiome's enzyme discovery and engineering platform to replace petroleum-derived raw materials in TOK products, supporting TOK Vision 2030 decarbonization goals.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint research agreement: bitBiome conducts a comprehensive search and screens new enzymes from bit-GEM, and Ajinomoto evaluates and verifies the usefulness of the enzymes for its healthcare, food & wellness, ICT, and green initiatives.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Strategic partnership bringing together bitBiome's bit-GEM database and Twist's DNA synthesis platform for enzyme development (particularly for synthesis of active pharmaceutical ingredients); expands reach of purpose-built enzymes to US and European labs; Twist also distributes bitBiome's enzyme screening kit.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Joint research agreement: bitBiome uses its microbial single-cell genome analysis to search for novel bacterial species and enzymes capable of degrading plastics and other non-biodegradable components by evaluating composting site samples (raw and enriched in PHB/PLA bioplastics).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo).

13Meiji
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo).

bitbiome.bio
14Japan Science and Technology Agency (JST)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo); Founder CSO Hosokawa is a JST PRESTO researcher (2015) and 2019 JST PRESTO Innovation Award recipient.

bitbiome.bio
15Kaken (JSPS KAKENHI)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo).

bitbiome.bio
16NEDO (New Energy and Industrial Technology Development Organization)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo). NEDO commissions multiple projects bitBiome participates in (Biomanufacturing Revolution Promotion Program with Kao, Sanwa Starch, Bell Polyester Products).

bitbiome.bio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo).

18Waseda University
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo). bitBiome originated from research at Waseda University by Founder CSO Masahito Hosokawa; HQ is co-located at Waseda University Research Innovation Center.

bitbiome.bio
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo).

Strategic tierMinorTypeOthers
Description

Listed as a partner/collaborator on bitBiome's Applications page (logo).

21AMED (Japan Agency for Medical Research and Development)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Adoption of bitBiome's endolysin therapeutic project under AMED's P-PROMOTE Next-Generation Cancer Medical Acceleration Research Program (June 2025), in collaboration with Nagoya University.

bitbiome.bio
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Codexis is a public enzyme engineering company specializing in biocatalysis for pharmaceutical and fine chemical manufacturing. It is the most directly comparable peer to BitBiome's bit-QED platform — both target novel enzyme discovery and directed evolution for industrial customers, and BitBiome has hired multiple former Codexis executives (CBO, Head of BD, advisors).

TypeDirect peer
Description

Carbios is a French biotech that uses engineered enzymes to depolymerize PET plastic into monomers for closed-loop recycling. It is a direct peer in the PETase enzyme development and bio-recycling vertical where BitBiome partners with Bell Polyester Products under NEDO funding.

TypeEmerging player
Description

Protein Evolution is an AI-and-biotechnology company focused on enzymatic recycling of textiles and mixed plastics. It is a direct emerging peer in the enzymatic plastic/textile recycling vertical where BitBiome partners with Bell Polyester Products.

TypeEmerging player
Description

Samsara Eco is an Australian biotech using engineered enzymes for infinite plastic recycling. It competes with BitBiome's bit-QED PETase development work and shares the same enterprise sustainability customer thesis around textile and packaging brands.

TypeDirect peer
Description

Antheia is a synthetic biology company engineering yeast strains to produce plant-based alkaloid APIs and fine chemicals at commercial scale. It is highly comparable to BitBiome's joint development manufacturing model in flavors & fragrances and pharma ingredients, and shares an advisor (John Nicols, Antheia Board Chair).

TypeEmerging player
Description

Generate Biomedicines is a generative AI biology company designing novel proteins across therapeutics and industrial applications. It is comparable to BitBiome's bit-QED platform as a next-generation AI protein design player, but focused primarily on therapeutics whereas BitBiome targets industrial enzymes.

TypeBroad incumbent
Description

Ginkgo Bioworks is a large, established synthetic biology platform serving pharma, food, and industrial customers via its cell engineering platform and Codon/Foundry services. It competes broadly with BitBiome in enzyme and strain engineering, but at a much larger scale and with a horizontal platform rather than BitBiome's vertically integrated sequencing-to-manufacturing approach.

TypeEmerging player
Description

Cradle uses generative AI to design novel proteins and enzymes for biotech customers. It is comparable to BitBiome's bit-QED AI-driven enzyme engineering platform, though Cradle focuses on generative protein design while bitBiome combines AI with proprietary single-cell sequencing data.

TypeEmerging player
Description

Bota Bio is an AI-driven biomanufacturing platform that designs and engineers microbes for sustainable production of ingredients across flavors & fragrances, personal care, and nutrition. It overlaps with BitBiome's enzyme discovery + strain engineering offering, particularly in flavor & fragrance biomanufacturing where both companies are pursuing enterprise deals.

TypeBroad incumbent
Description

LanzaTech is a commercial-scale gas fermentation biomanufacturing company producing sustainable fuels and chemicals from waste gases. It is comparable to BitBiome in commercial biomanufacturing ambition and customer base (industrial / specialty chemical / fuel majors), but uses carbon capture gas fermentation rather than enzyme-driven bioconversion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BitBiome

Microbial Genomics & Enzyme Engineering Servicesbitbiome.bio

BitBiome is a Tokyo-based microbial genomics company combining proprietary single-cell sequencing, a 2.5B+ sequence database, and AI-driven enzyme engineering to serve industrial biotech customers in food, chemicals, personal care, animal health, and bio-recycling.

What BitBiome does

BitBiome is a Tokyo-headquartered biotechnology company, founded in 2018, that operates a vertically integrated platform for microbial genomics and AI-driven enzyme engineering. The platform has three core components: bit-MAP, a proprietary single-cell microbial genome sequencing technology; bit-GEM, a proprietary microbial genome database containing more than 2.5 billion sequences of which approximately 50% are novel; and bit-QED, an AI/ML-based enzyme design platform that combines structural modeling, large language models, and in silico directed evolution. BitBiome also maintains a US presence in Palo Alto, California, supporting commercial and partnership activity in North America.

The company sells into industrial biotechnology customers across food and ingredients (Ajinomoto, Sanwa Starch), specialty chemicals (Tokyo Ohka Kogyo), personal care (Kao), textiles and bio-recycling (Bell Polyester under NEDO funding), animal health (Kyoritsu Seiyaku), distribution (Tojo Vikas for India), and life sciences tools (Twist Bioscience for enzyme kit distribution), plus an unnamed flavors and fragrances market leader. Revenue is generated through a mix of custom sequencing service contracts, joint development agreements with milestone or licensing components, grant-funded research programs (NEDO and AMED), and an emerging standardized enzyme/reagent kit channel via Twist Bioscience. Total capital raised across equity and non-dilutive funding exceeds $45M as of a 2026 oversubscribed seed extension, with strategic participation from IQT, IT-Farm, Valuence Ventures, and Darwin Ventures. The company was named to the Forbes Asia 100 To Watch list in 2025.

The business model is best characterized as a hybrid services-plus-platform model: short- to medium-term cash flow comes from sequencing services and JDAs, non-dilutive grant income supports longer-horizon platform R&D, and the strategic optionality of bit-QED and bit-GEM is positioned to generate higher-margin licensing or royalty income over time as customer programs mature.

BitBiome firmographics

Firmographics
Name
BitBiome
Legal name
bitBiome, Inc.
Website
https://bitbiome.bio
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
BitBiome is a Tokyo-based microbial genomics company combining proprietary single-cell sequencing, a 2.5B+ sequence database, and AI-driven enzyme engineering to serve industrial biotech customers in food, chemicals, personal care, animal health, and bio-recycling.
Ownership category
akta.pro rank

BitBiome industry classification

Industry
Product category
Microbial Genomics & Enzyme Engineering Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Microbial genome sequencing
  • Enzyme engineering services
  • Synthetic biology platform
  • Biomanufacturing solutions
  • Metagenomics database

Where BitBiome is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

BitBiome business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Enzyme Discovery, Engineering, and Strain Development Services: Custom B2B fee-for-service revenue from database mining, assaying, directed evolution, and strain engineering using bit-QED. Engagement is typically project-based with flexible scope (single-step to end-to-end workflow including wet lab validation and production).
  2. Sequencing Services (bit-MAP®): Fee-based single-cell microbial sequencing services delivered via a Collect → Ship → Receive Report workflow with full bioinformatics report (taxonomies, novelty, completeness, contamination). Includes human, animal, and environmental samples.
  3. Enzyme Kit Product Sales (via Twist Bioscience): bitBiome's enzyme screening kit (48 validated transaminases across 18 substrates with freeze-dried enzymes, yielding 1,800 variants after six rounds of refinement) is commercialized through Twist Bioscience's storefront. Revenue likely flows via distribution agreement.
  4. Joint Development, Manufacturing & Supply Partnerships: Revenue from joint development and manufacturing collaborations where bitBiome develops bio-based production processes and serves as manufacturing/supply partner upon commercialization (e.g., food-grade flavor & fragrance ingredient collaboration with double-digit metric ton annual demand; PET bio-recycling with Bell Polyester Products).
  5. Public/Grant (Non-Dilutive) Funding: bitBiome receives non-dilutive funding from Japanese government programs (NEDO Biomanufacturing Revolution Promotion Program; AMED P-PROMOTE Next-Generation Cancer Medical Acceleration Research Project with Nagoya University; JST PRESTO), which supplements its commercial revenue streams.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

BitBiome product offering

Product offering

Core offering

BitBiome provides a microbial biomanufacturing platform combining proprietary single-cell microbial genome sequencing (bit-MAP®), a proprietary microbial sequence database (bit-GEM, 2.5B+ sequences), and an AI-driven enzyme and strain engineering platform (bit-QED) that uses bioinformatics, cheminformatics, machine learning, and large language models for in silico enzyme design and directed evolution. The platform is delivered to enterprise customers as fee-for-service sequencing, custom enzyme discovery and engineering, and joint development/manufacturing partnerships spanning pharmaceuticals, food & agriculture, materials & plastics, flavors & fragrances, and life science tools.

Product overview

bitBiome operates a unified microbial biomanufacturing platform built around three tightly integrated core modules: bit-MAP® (the patented single-cell microbial sequencing engine that powers data generation), bit-GEM (the proprietary microbial genome catalog of 2.5+ billion sequences grown from bit-MAP outputs), and bit-QED (the AI-driven enzyme discovery, engineering, and strain development platform that mines and engineers sequences from bit-GEM). These three modules together form the foundation of the offering, which is delivered to customers through complementary products and services: Sequencing Services (single-cell sequencing-as-a-service with bioinformatics reporting) and a commercial Enzyme Kit (a Twist Bioscience-distributed transaminase screening kit for ownable enzyme development). The platform also supports internal R&D pipeline development across Food & Agriculture, Materials & Textiles, Plastics, Drug Discovery, Drug Biomanufacturing, Synbio, and Gene Editing applications, and is positioned as a one-stop-shop from microbial discovery through commercial-scale biomanufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • bit-MAP®: bitBiome's patented single-cell sequencing technology for microbes using microfluidics to capture and sequence individual bacterial genomes within isolated capsules; 100x more efficient than shotgun metagenomics.
  • bit-GEM
  • bit-QED

Products and services

  • bit-MAP® Patented single-cell microbial sequencing technology that uses microfluidics to capture and sequence individual bacterial genomes inside isolated capsules, eliminating the need for culturing. Reported as 100x more efficient than shotgun metagenomics and capable of recovering microbial dark matter from low-biomass and high-diversity samples. Foundation of BitBiome's platform.
  • bit-GEM Proprietary microbial genome database of 2.5 billion sequences (and growing by ~1 billion per year) built on bit-MAP single-cell sequencing of microbes from natural samples, including unculturable and extremophile sources. Approximately 60% of samples are environmental and ~50% taxonomically novel compared with public databases.
  • bit-QED AI-driven enzyme discovery, engineering, and strain development platform that combines sequence and structure-based mining of bit-GEM with machine learning, large language models, 3D structural modeling, and automated wet-lab high-throughput screening. Reduces a 2-3 year process to months or weeks and is positioned as a one-stop-shop for biomanufacturing.
  • Sequencing Services Single-cell microbial sequencing-as-a-service: customers collect human/animal/environmental samples and ship them to bitBiome, which delivers a full bioinformatics report including taxonomies. Includes a miniaturized multi-drop metagenomics workflow providing 10x the data while retaining single-cell resolution.
  • Enzyme Kit (Transaminase Screening Kit) Kick-start enzyme development kit leveraging 48 validated unique transaminases tested against 18 different substrates, delivered as freeze-dried enzymes. Six rounds of bitBiome's bioinformatics and refinement yield 1,800 new variants for testing. Commercialized in partnership with Twist Bioscience.

Quantifiable outcome

  • 100x more efficient gene analysis than shotgun metagenomics
  • +8 more outcomes

Companies that use BitBiome

Customer profile

Named customers11 records

Segments7 records

Ideal customer profiles6 records

BitBiome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

BitBiome partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered major, flagship and minor.

  • Kyoritsu Seiyaku CorporationmajorStrategic or Co-development Partner · 9 March 2026Strategic collaboration to jointly develop products utilizing bitBiome's bio-manufacturing technologies for animal health and nutrition. Kyoritsu Seiyaku contributes decades of veterinary experience for pets and livestock; commercialize jointly in global market.
  • Unnamed major market leader in flavors & fragrancesmajorStrategic or Co-development Partner · 3 March 2026Joint development and manufacturing collaboration to create a bio-synthetic production process for a high-value food-grade ingredient used in flavors and fragrances. Initial demand projected at double-digit metric tons per year.
  • Kao CorporationflagshipStrategic or Co-development Partner · 17 February 2026Joint implementation of NEDO-commissioned 'Research and Development of Technologies to Promote Biomanufacturing' project to establish a saccharification enzyme supply platform that enables use of unused biomass resources. bitBiome handles enzyme discovery work.
  • Tojo Vikas International Pvt. Ltd.majorStrategic or Co-development Partner · 29 January 2026Strategic joint development and commercialization collaboration for sustainable flavor and fragrance biomanufacturing. Combines bitBiome's proprietary microbial database and bio-manufacturing platform with Tojo Vikas' market knowledge and ingredient commercialization expertise.
  • Bell Polyester Products Co., Ltd.majorStrategic or Co-development Partner · 6 August 2025Selected together for NEDO 'Bio-recycling of Waste Plastic Resources' project — bitBiome develops proprietary enzymes using bit-QED, Bell Polyester Products produces bio-recycled co-polymerized PET resin via Bio BellPET line.
  • Sanwa Starch Co., Ltd.majorStrategic or Co-development Partner · 7 July 2025Enzyme development contract under NEDO Biomanufacturing project 'Development and Social Implementation of Functional Sugar Materials from Untapped Domestic Biomass.' bitBiome uses bit-QED to discover and supply saccharification enzymes.
  • Nagoya University (Tokai National Higher Education and Research System)majorStrategic or Co-development Partner · 16 June 2025Collaboration under AMED P-PROMOTE Next-Generation Cancer Medical Acceleration Research Project to develop combination therapy of Fusobacterium-specific endolysin and immune checkpoint inhibitors for ovarian cancer.
  • Tokyo Ohka Kogyo Co., Ltd. (TOK)flagshipStrategic or Co-development Partner · 30 January 2024Joint development agreement to develop bio-processes using bitBiome's enzyme discovery and engineering platform to replace petroleum-derived raw materials in TOK products, supporting TOK Vision 2030 decarbonization goals.
  • Ajinomoto Co., Inc.flagshipStrategic or Co-development PartnerJoint research agreement: bitBiome conducts a comprehensive search and screens new enzymes from bit-GEM, and Ajinomoto evaluates and verifies the usefulness of the enzymes for its healthcare, food & wellness, ICT, and green initiatives.
  • Twist BioscienceflagshipStrategic or Co-development PartnerStrategic partnership bringing together bitBiome's bit-GEM database and Twist's DNA synthesis platform for enzyme development (particularly for synthesis of active pharmaceutical ingredients); expands reach of purpose-built enzymes to US and European labs; Twist also distributes bitBiome's enzyme screening kit.
  • The University of Texas at Austin (Dr. Alper's laboratory)majorStrategic or Co-development PartnerJoint research agreement: bitBiome uses its microbial single-cell genome analysis to search for novel bacterial species and enzymes capable of degrading plastics and other non-biodegradable components by evaluating composting site samples (raw and enriched in PHB/PLA bioplastics).
  • Université de MontréalminorStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo).
  • MeijiminorStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo).
  • Japan Science and Technology Agency (JST)majorStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo); Founder CSO Hosokawa is a JST PRESTO researcher (2015) and 2019 JST PRESTO Innovation Award recipient.
  • Kaken (JSPS KAKENHI)minorStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo).
  • NEDO (New Energy and Industrial Technology Development Organization)flagshipStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo). NEDO commissions multiple projects bitBiome participates in (Biomanufacturing Revolution Promotion Program with Kao, Sanwa Starch, Bell Polyester Products).
  • Universal Materials Incubator (UMI)minorStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo).
  • Waseda UniversityflagshipStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo). bitBiome originated from research at Waseda University by Founder CSO Masahito Hosokawa; HQ is co-located at Waseda University Research Innovation Center.
  • FujifilmminorStrategic or Co-development PartnerListed as a partner/collaborator on bitBiome's Applications page (logo).
  • NCCJminorOthersListed as a partner/collaborator on bitBiome's Applications page (logo).
  • AMED (Japan Agency for Medical Research and Development)majorStrategic or Co-development PartnerAdoption of bitBiome's endolysin therapeutic project under AMED's P-PROMOTE Next-Generation Cancer Medical Acceleration Research Program (June 2025), in collaboration with Nagoya University.

Scale indicators13 records

Recent moves6 records

Expansion highlights7 records

BitBiome competitors and assessment

Company assessment

Direct peers

  • Codexis: Codexis is a public enzyme engineering company specializing in biocatalysis for pharmaceutical and fine chemical manufacturing. It is the most directly comparable peer to BitBiome's bit-QED platform — both target novel enzyme discovery and directed evolution for industrial customers, and BitBiome has hired multiple former Codexis executives (CBO, Head of BD, advisors).
  • Carbios: Carbios is a French biotech that uses engineered enzymes to depolymerize PET plastic into monomers for closed-loop recycling. It is a direct peer in the PETase enzyme development and bio-recycling vertical where BitBiome partners with Bell Polyester Products under NEDO funding.
  • Antheia: Antheia is a synthetic biology company engineering yeast strains to produce plant-based alkaloid APIs and fine chemicals at commercial scale. It is highly comparable to BitBiome's joint development manufacturing model in flavors & fragrances and pharma ingredients, and shares an advisor (John Nicols, Antheia Board Chair).

Emerging players

  • Protein Evolution: Protein Evolution is an AI-and-biotechnology company focused on enzymatic recycling of textiles and mixed plastics. It is a direct emerging peer in the enzymatic plastic/textile recycling vertical where BitBiome partners with Bell Polyester Products.
  • Samsara Eco: Samsara Eco is an Australian biotech using engineered enzymes for infinite plastic recycling. It competes with BitBiome's bit-QED PETase development work and shares the same enterprise sustainability customer thesis around textile and packaging brands.
  • Generate Biomedicines: Generate Biomedicines is a generative AI biology company designing novel proteins across therapeutics and industrial applications. It is comparable to BitBiome's bit-QED platform as a next-generation AI protein design player, but focused primarily on therapeutics whereas BitBiome targets industrial enzymes.
  • Cradle Bio: Cradle uses generative AI to design novel proteins and enzymes for biotech customers. It is comparable to BitBiome's bit-QED AI-driven enzyme engineering platform, though Cradle focuses on generative protein design while bitBiome combines AI with proprietary single-cell sequencing data.
  • Bota Bio: Bota Bio is an AI-driven biomanufacturing platform that designs and engineers microbes for sustainable production of ingredients across flavors & fragrances, personal care, and nutrition. It overlaps with BitBiome's enzyme discovery + strain engineering offering, particularly in flavor & fragrance biomanufacturing where both companies are pursuing enterprise deals.

Broad incumbents

  • Ginkgo Bioworks: Ginkgo Bioworks is a large, established synthetic biology platform serving pharma, food, and industrial customers via its cell engineering platform and Codon/Foundry services. It competes broadly with BitBiome in enzyme and strain engineering, but at a much larger scale and with a horizontal platform rather than BitBiome's vertically integrated sequencing-to-manufacturing approach.
  • LanzaTech: LanzaTech is a commercial-scale gas fermentation biomanufacturing company producing sustainable fuels and chemicals from waste gases. It is comparable to BitBiome in commercial biomanufacturing ambition and customer base (industrial / specialty chemical / fuel majors), but uses carbon capture gas fermentation rather than enzyme-driven bioconversion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BitBiome social profiles

Digital presence

BitBiome compliance and trust

Trust signal

Compliance1 record

BitBiome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BitBiome leadership team

Management profile

Number of profiles

Profiles7 records

BitBiome subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BitBiome funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BitBiome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BitBiome

What does BitBiome do?

BitBiome provides a microbial biomanufacturing platform combining proprietary single-cell microbial genome sequencing (bit-MAP®), a proprietary microbial sequence database (bit-GEM, 2.5B+ sequences), and an AI-driven enzyme and strain engineering platform (bit-QED) that uses bioinformatics, cheminformatics, machine learning, and large language models for in silico enzyme design and directed evolution. The platform is delivered to enterprise customers as fee-for-service sequencing, custom enzyme discovery and engineering, and joint development/manufacturing partnerships spanning pharmaceuticals, food & agriculture, materials & plastics, flavors & fragrances, and life science tools.

Is BitBiome a public or private company?

BitBiome is a private company. It is classified as venture growth investor backed and is currently operating.

When was BitBiome founded?

BitBiome was founded in 2018. It employs 51 to 100 people.

Where is BitBiome based?

BitBiome is headquartered in Tokyo, Japan, in the Asia region.

How does BitBiome make money?

Five revenue lines are on record. Enzyme Discovery, Engineering, and Strain Development Services are the primary driver. The others are sequencing Services (bit-MAP®), enzyme Kit Product Sales (via Twist Bioscience), joint Development, Manufacturing & Supply Partnerships and public/Grant (Non-Dilutive) Funding.

Who are BitBiome's main competitors?

Direct peers on record are Codexis, Carbios and Antheia. Emerging players are Protein Evolution, Samsara Eco, Generate Biomedicines, Cradle Bio and Bota Bio. Broad incumbents are Ginkgo Bioworks and LanzaTech.

Does BitBiome have an API?

No public API is recorded for BitBiome.

What industry is BitBiome in?

BitBiome's product category is Microbial Genomics & Enzyme Engineering Services. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAH, Microbiome & Metagenomics Services. Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesCraif, one of the largest conferences in the domestic bio AI field, announces the third round of speakers for the 'Bio AI Summit 2026'.Craif Inc. announced Toshio Fujimoto, president of iPark Institute, as the third speaker for the Bio-AI Summit 2026 on September 17, 2026. The summit, organized by the Bio-AI Council with support from Tokyo, LINK-J, and JST, will be held at Tokyo Innovation Base. The event aims to position Japan's bio-AI on the global stage.Thebridge産業利用可能な微生物株や酵素の探索・開発を手掛けるbitBiome、UPSIDER BLUE DREAM Fund から5億円の融資枠を獲得BitBiome, a biotech firm developing industrial microbial strains and enzymes, received a 500 million yen loan from UPSIDER BLUE DREAM Fund on the 27th. The funds will expand data and AI infrastructure and accelerate product development for bio-manufacturing.Pulse 2.0bitBiome: Seed Extension Round Closed To Advance AI-Driven Enzyme Discovery PlatformbitBiome announced it has closed an oversubscribed seed extension round, bringing its combined equity and non-dilutive funding, including grants, to over $45 million. The Tokyo and Palo Alto-based company focuses on AI-driven enzyme discovery and engineering using its proprietary microbial database of more than 3 billion sequences. The funding will be used to accelerate microbial enzyme and pathway development, expand the company's global footprint, and strengthen partnerships across industrial biotechnology, pharmaceuticals, synthetic biology, and biomanufacturing sectors.PrtimesZoom、Treasure DataやTwist Bioscienceを知るグローバル投資家が語る、bitBiomeへの投資理由。Bio×AIの未来に迫る特別インタビュー第1弾を「note」にて公開bitBiome announced its third seed extension round investment from global investors, including IT-Farm, and will publish interviews on note. The company's microbial single-cell genome analysis technology has built a database of over 3 billion sequences, and it is developing its SENS-AI model. The interviews aim to discuss the Bio×AI field's potential.citybizbitBiome Closes Oversubscribed Seed Extension as Investors Double Down on AI-Driven Biomanufacturing PlatformsbitBiome has closed an oversubscribed seed extension round, bringing its combined equity and non-dilutive funding to more than $45 million, though the specific round size was not disclosed. The funding will support expansion of the company's microbial database (bit-GEM), AI modeling capabilities, and commercialization partnerships across industrial biotech, pharmaceuticals, and synthetic biology sectors. The round attracted participation from investors including IQT and Valuence Ventures, who cited the strategic value of bitBiome's proprietary genomic dataset and enzyme engineering platform.PR NewswirebitBiome Closes Oversubscribed Seed Extension RoundbitBiome, a Tokyo-based biotechnology company specializing in enzyme and protein engineering, has closed an oversubscribed seed extension round, bringing its total equity and non-dilutive funding to over $45 million. The funding round was led by multiple investors including IQT, IT-Farm, Valuence Ventures, and Darwin Ventures. The company plans to use the capital to expand its AI-enabled microbial database and modeling platform, deepen its modeling-first approach to enzyme engineering, and grow its global presence across industrial biotech, pharma, and biomanufacturing sectors.PrtimesbitBiome has completed the seed extension round. The total amount raised is 7 billion yen.bitBiome closed its seed extension round, raising approximately 3.5 billion yen in equity, debt, and grants, bringing cumulative funding to 7 billion yen. The company will use the funds to expand its microbial database and AI platform, aiming for product launches within a few years.PR NewswirebitBiome and Kyoritsu Seiyaku Announce Strategic Collaboration in Animal Health and NutritionbitBiome, Inc., a biotechnology company specializing in bio-manufactured products, announced a joint development and collaboration agreement with Kyoritsu Seiyaku Corporation, a Japanese animal health company, to co-develop products using advanced biotechnology for animal health and nutrition applications. Under the agreement, bitBiome will leverage its microbial sequence database and enzyme technology platform while combining it with Kyoritsu Seiyaku's veterinary medicine expertise to commercialize biological solutions for livestock and pets in the global market.PrtimesbitBiome and Kyoritsu Seiyaku announce a strategic collaboration in the field of animal health and nutrition.bitBiome Inc. and Kyoritsu Seiyaku Co., Ltd. announced a strategic collaboration to jointly develop products utilizing new bio-manufacturing technologies for applications in animal health and nutrition. bitBiome will leverage its platform integrating the world's largest microbial sequence database, enzyme engineering, and genome modification technology, while Kyoritsu Seiyaku contributes its decades of experience in animal pharmaceuticals for pets and livestock. The partnership aims to commercialize developed technologies in the global market and address global challenges related to animal health and sustainability.PR NewswirebitBiome Announces Major Collaboration Agreement in Commercial-Scale Bio-Manufacturing of Food-Grade IngredientbitBiome announced a joint development and manufacturing collaboration to develop a bio-synthetic production process for a high-value, food-grade ingredient used in the flavor and fragrance industry, with an unnamed commercial partner that holds a significant majority share of the worldwide market. Under the agreement, bitBiome is responsible for developing and implementing the production process and will serve as the manufacturing and supply partner upon commercialization, with initial demand projected at double-digit metric tons per year during early commercialization. The collaboration aims to transition production from conventional methods to a scalable, food-grade, bio-based manufacturing platform, leveraging bitBiome's AI-powered genome-scale bioengineering capabilities.